Recent developments in mycosis fungoides therapy include oral and topical bexarotene, a retinoid X receptor–selective retinoid1,2 that has activity in all stages of cutaneous T-cell lymphoma.2-4 We describe a 75-year-old patient with long-standing mycosis fungoides recalcitrant to established skin-directed treatment regimens who responded rapidly to therapy with a combination of oral bexarotene and psoralen plus ultraviolet A (PUVA) bath therapy.